$MBX News

Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio - Slideshow

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript

Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70

MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Pharmacokinetic Profile Supporting Potential For Once-Monthly Dosing And Competitive Weight Loss In First MAD Cohort

MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate

Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know

Microbix Announces Annual Meeting Voting Results

Microbix Presents Reference-Material Innovations at EUROGIN

MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus

MBX Biosciences Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

MBX Biosciences Announces End-of-Phase 2 FDA Meeting Results and Provides Phase 3 Development Plan For Canvuparatide